RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro is probably busy at the SFN, but concerning the non-Ampakine in-licensing strategy, I wonder if there might conceivably be a situation out there where a company has a drug that's already approved and marketed for a larger indication, but which might also have potential activity for an orphan indication. The orphan indication is too small for the pharma company to bother with, but perfect for a small outfit like Cortex. Cortex then in-licenses the drug, and runs the small orphan trials. If the drug is already approved for a larger indication, that would eliminate much of the risk from Cortex's perspective. Just wondering if this might be a possibility, as opposed to a brand new drug entity, with all the risk that entails.